# Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

> clinical trial · VERIFIED · 2026-07-10

Status: RECRUITING · Sponsor: BeiGene · Condition: MSI-H/dMMR Solid Tumors

- Company: BeiGene
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT03736889

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.